Executive Summary
Hemostemix Inc. ($HEM: TSXV) is a clinical-stage biotechnology company based in Calgary, Canada. The company specializes in the development, manufacturing, and sales of blood-derived stem cell therapies for a variety of diseases. Hemostemix’s approach is to use a patient’s own blood as a non-invasive source of therapeutic cells. Hemostemix was recognized for its innovative efforts in the field of stem cell therapy. Being the recipient of the World Economic Forum’s Technology Pioneer Award, it recognizes the company’s contributions to the advancement of technology and healthcare. $HEM share price stood at $0.065 and had a market cap of $5,662,952. Next, the company had a decent trading volume of 101,000 on Dec 26, 2023.
Introduction
Hemostemix Inc. is focused on harnessing the potential of blood stem cells to develop effective, personalized treatments for a variety of medical diseases, especially vascular diseases. One of the company’s flagship products is ACP-01, an autologous cell therapy. ACP-01 is currently undergoing Phase II clinical trials in Canada and the United States for the treatment of heart disease.
In addition to ACP-01, Hemostemix is actively developing other types of cell products. These include synergistic cell populations, which are combinations of different cell types that work together to enhance therapeutic efficacy. The company is also working on neural precursors, which can develop into different types of nerve cells, and cardiomyocyte precursors, which can develop into cardiomyocytes. Autologous cell therapy is a treatment approach where a patient’s own cells are used to develop therapeutic products, thereby potentially reducing the risk of rejection or immune reactions.
Problem Statement
Stem cell technology is a rapidly evolving field that combines the efforts of cell biologists, geneticists, and clinicians, and holds promise for effective treatment of a variety of malignant and non-malignant diseases. Though stem cell therapy is a buzzword in the biotechnology and clinical industry, the company’s growth was not reflected in its stock market performance. The company’s share price was low, with low demand, and relatively low trading volume. The company was expecting a share price rise as its financial fundamentals were strong with an emerging stem cell therapy industry. As a professional IR company, we saw the potential lacunas in the company’s stock promotion activities.
Problem Identification and Methodology
As a professional IR company, when we made a thorough analysis of its stock market performance, it was lacking well- directed investor relation campaigns and stock promotion activities. There was a desperate need for the circulation of the company’s growth prospects and growth stories in the long term. The investor community should know about the growth prospects involved in the long-run so that they would be drawn towards its shares. The share price can be increased only when there is a rise in demand for its shares or should have a positive investor sentiment in the stock market.
For this, there was a need for implementing various IR strategies such as Social Media Management, Influencer Marketing, Video Production and marketing, YouTube shoot-making, and marketing, Media publishing, and media Relations, Press Releases, Investor & Community Relations, and PPC marketing.
Solutions Implemented
First, our IR team had a detailed discussion with our CEO and revealed the campaigns to be launched at the same time. After our CEO’s final node, the IR team began to act as per the plans earlier discussed. All of the campaign strategies were accelerated and all were directed at driving share price growth. The company was riddled with high selling demand leading to a share price fall. That was prevented and brought stability to share price volatility. One-to-one online marketing campaigns were started to bring credibility and visibility to the market.
Results & Outcomes
Sustained IR and social media marketing efforts were coordinated under able guidance of our experienced CEO who has a decade of experience in IR and PR activities. With relentless effort from our content and social media team, we derived traction for the company in the stock market. We drew the attention of the investors for its shares and growth opportunities in the form of ROI. The strategy paid off and its share price started increasing. Thanks to our IR team that made things possible!